WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors

Yuji Sakuma(Sapporo Medical University), Yohei Miyagi(Kanagawa Prefectural Hospital Organization)
Laboratory Investigation
December 12, 2011
Cited by 47


Related Papers